ClinicalTrials.gg
CompletedNCT00284050RESOLVEUpdated Feb 24, 2011Results posted

Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement

A Phase 2 interventional study of Ranibizumab 0.3 mg and Ranibizumab 0.5 mg in Diabetic Macular Edema, sponsored by Novartis. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-02-24.

Sponsored by Novartis · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.

Enrollment
26th of 91
151 · median 50
Started
2005
the only one that year
Phase 2
19 of 91
none open now
Registered
2nd of 91
by date

Among the 91 studies testing ranibizumab in Macular Edema, this one is the 26th largest by enrollment, is the only one that started in 2005, is one of 19 in phase 2, and was the 2nd registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 91 studies testing ranibizumab in Macular Edema as a file.
02

Study summary

This study evaluated the safety and efficacy of ranibizumab on retinal edema and visual acuity in patients with diabetic macular edema with center involvement.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • DME
  • Diabetic macular edema
  • ranibizumab
  • Diabetic macular edema with center involvement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diabetic macular edema with center involvement in at least one eye
  • Type 1 or type 2 diabetes mellitus diagnosed 2 years prior to screening
  • Laser photocoagulation in the study eye can be withheld for at least 3 months after randomization

Exclusion criteria

Exclusion Criteria:

  • Patients with uncontrolled systemic or ocular diseases
  • Have any history of any intraocular surgery in the study eye within the past 6 months preceding screening
  • Conditions that require chronic concomitant therapy with systemic or topical ocular

Other protocol-defined inclusion/exclusion criteria applied to the study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Ranibizumab 0.3 mg

    Participants received monthly intravitreal injections with 0.3 mg ranibizumab (6 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 0.6 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.

    Drug: Ranibizumab 0.3 mg

  • Experimental
    Ranibizumab 0.5 mg

    Participants received monthly intravitreal injections with 0.5 mg ranibizumab (10 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 1.0 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.

    Drug: Ranibizumab 0.5 mg

  • Sham comparator
    Sham injection

    Participants in the control group received 12 monthly sham intravitreal injections. The evaluation was performed using the same criteria for dose doubling as in active treatment groups. The injection was a mimicked by an empty syringe without a needle. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.

    Drug: Sham injection

Interventions

  • 6 mg/ml ranibizumab solution for intravitreal injection

  • 10 mg/ml ranibizumab solution for intravitreal injection

  • DrugSham injection

    Non-treatment control for sham intravitreal injection.

06

What researchers measure

Primary outcomes

  1. Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From Month 1 to Month 12

    Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters as described in the Study Operations Manual.

    Time frame: Baseline through the end of study (Month 12)

  2. Mean Change From Baseline in Visual Acuity (Letters) of the Study Eye at Month 12

    Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters as described in the Study Operations Manual.

    Time frame: Baseline through the end of study (Month 12)

Secondary outcomes

  1. Mean Change From Baseline in Central Retinal Thickness (µm) of the Study Eye at Month 12

    Optical Coherence Tomography (OCT) was assessed on both eyes at every study visit. These assessments were performed by trained personnel at the sites. OCT imaging was performed using the Zeiss Humphrey System Model 2000 (or later) with version A6.1 software running under Windows 95 or Windows 98. The analysis of the OCT images were performed by the Photographic Reading Center which provided a study manual and training materials. OCT operators, systems and software were certified prior to any evaluation of study patients.

    Time frame: Baseline through the end of study (Month 12)

07

Results

Posted Jan 20, 2011

Participant flow

Participant flow — Overall Study
MilestoneRanibizumab 0.3 mgRanibizumab 0.5 mgSham Injection
Started515149
Completed464640
Not completed559
Withdrew: Adverse event111
Withdrew: Lack of efficacy013
Withdrew: Protocol violation012
Withdrew: Withdrawal by subject222
Withdrew: Lost to follow-up101
Withdrew: Death100

Outcome measures

PrimaryDifference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From Month 1 to Month 12

Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters as described in the Study Operations Manual.

Time frame:
Baseline through the end of study (Month 12)
Reported as:
Mean · Letters
Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From Month 1 to Month 12
LettersRanibizumab 0.3 mgRanibizumab 0.5 mgSham Injection
Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From Month 1 to Month 129.2 ± 5.606.4 ± 9.21-0.1 ± 9.77
PrimaryMean Change From Baseline in Visual Acuity (Letters) of the Study Eye at Month 12

Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters as described in the Study Operations Manual.

Time frame:
Baseline through the end of study (Month 12)
Reported as:
Mean · Letters
Mean Change From Baseline in Visual Acuity (Letters) of the Study Eye at Month 12
LettersRanibizumab 0.3 mgRanibizumab 0.5 mgSham Injection
Mean Change From Baseline in Visual Acuity (Letters) of the Study Eye at Month 1211.8 ± 6.598.8 ± 10.99-1.4 ± 14.16
SecondaryMean Change From Baseline in Central Retinal Thickness (µm) of the Study Eye at Month 12

Optical Coherence Tomography (OCT) was assessed on both eyes at every study visit. These assessments were performed by trained personnel at the sites. OCT imaging was performed using the Zeiss Humphrey System Model 2000 (or later) with version A6.1 software running under Windows 95 or Windows 98. The analysis of the OCT images were performed by the Photographic Reading Center which provided a study manual and training materials. OCT operators, systems and software were certified prior to any evaluation of study patients.

Time frame:
Baseline through the end of study (Month 12)
Reported as:
Mean · µm
Mean Change From Baseline in Central Retinal Thickness (µm) of the Study Eye at Month 12
µmRanibizumab 0.3 mgRanibizumab 0.5 mgSham Injection
Mean Change From Baseline in Central Retinal Thickness (µm) of the Study Eye at Month 12-200.7 ± 122.18-187.6 ± 147.82-48.4 ± 153.43

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.3 mg—9/51 (17.6%)37/51 (72.5%)
Ranibizumab 0.5 mg—9/51 (17.6%)43/51 (84.3%)
Sham Injection—9/49 (18.4%)32/49 (65.3%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventRanibizumab 0.3 mgRanibizumab 0.5 mgSham Injection
Angina pectorisCardiac disorders0/510/511/49
Myocardial infarctionCardiac disorders0/511/511/49
Retinal detachment (Study eye)Eye disorders0/510/511/49
Pitting oedemaGeneral disorders0/510/511/49
CellulitisInfections and infestations0/510/511/49
Diabetic gangreneInfections and infestations0/510/511/49
GastroenteritisInfections and infestations0/510/511/49
Diabetes mellitus inadequate controlMetabolism and nutrition disorders0/510/511/49
Back painMusculoskeletal and connective tissue disorders0/510/511/49
Renal failureRenal and urinary disorders0/510/511/49
Most frequent other events
Showing 10 of 30
Most frequent other events
EventRanibizumab 0.3 mgRanibizumab 0.5 mgSham Injection
Intraocular pressure increased (Study eye)Investigations6/5115/511/49
Conjunctival haemorrhage (Study eye)Eye disorders10/5113/517/49
Eye pain (Study eye)Eye disorders9/519/5110/49
Vitreous floaters (Study eye)Eye disorders1/518/510/49
Visual acuity reduced (Study eye)Eye disorders1/516/515/49
NasopharyngitisInfections and infestations5/515/511/49
Conjunctivitis (Fellow eye)Eye disorders1/510/514/49
Conjunctivitis (Study eye)Eye disorders1/511/514/49
Ocular hyperaemia (Study eye)Eye disorders2/512/514/49
Retinal exudates (Study eye)Eye disorders2/511/514/49

Baseline characteristics

Age Continuous
Age Continuous(years)Ranibizumab 0.3 mgRanibizumab 0.5 mgSham InjectionTotal
Mean63.2 ± 10.4462.8 ± 10.1465.0 ± 9.2663.6 ± 9.95
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab 0.3 mgRanibizumab 0.5 mgSham InjectionTotal
Female22242470
Male29272581
08

Study locations

1 site
  • Novartis
    Basel, Switzerland
09

References and documents

Publications

  • Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010 Nov;33(11):2399-405. doi: 10.2337/dc10-0493. PubMed 20980427 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2006
First posted
Jan 31, 2006
Start
Oct 2005
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Jan 20, 2011
Last update
Feb 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00284050
Lead sponsor
Novartis
First posted
Jan 31, 2006
Start date
Oct 2005
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Jan 20, 2011
Last update
Feb 24, 2011

Study contacts

Novartis
study chair · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion